Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia (RODEO)
2024-516511-24-00Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imatinib, ponatinib, bosutinib, nilotinib and dasatinib in chronic myelogenous leukemia (CML), sponsored by Radboud University Medical Center. Primary endpoint: Treatment failure at 12 months after first dose reduction. Started Nov 2024; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-516511-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516511-24-00.